{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy.","groups":[{"description":"Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.\n\nMethotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).\n\nCyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).","id":"OG000","title":"Recipient"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day+14","title":"Percentage of Recipients Who Achieved Donor Chimerism at Day +14","type":"SECONDARY","unitOfMeasure":"percentage of recipients"}